David Dearden, a professor in the BYU Department of Chemistry and Biochemistry, is doing foundational work in the field of analytical chemistry. Dearden is a scholar in the field of mass spectrometry.

Advancing small molecules from R&D to GMP requires coordinated strategies to support phase I clinical manufacturing.

A new research effort is accelerating imaging techniques to visualize structures of small molecules clearly -- a process once thought impossible. Their discovery unleashes endless potential in ...

Another day, another artificial intelligence (AI) deal. Tuesday was Sanofi’s turn to partner up, striking a deal worth up to $140 million to work on the discovery of small molecules with its ...

This hands-on course teaches step-by-step techniques for interpreting mass spectrometric data to identify molecular structures. Participants will learn elemental composition analysis, tandem MS ...

As the science of drug discovery has grown in scale and gotten more complicated, so have the drug molecules themselves. But there’s a promising class of drugs made of just a handful of atoms that ...

Dec 3 (Reuters) - Excelsior Sciences said on Wednesday it has raised $95 million to develop technology that uses machines and artificial intelligence to accelerate the development and testing of small ...

In a study published in Nature Communications, they show that the metabolite L-arginine enhances the stability of protein ...